The free‐radical three‐component carbocyanation of electron‐rich olefins was investigated with p‐tosyl cyanide as cyanide source. The scope and limitations of the process were established by varying the nature of the alkene and radical precursor. Carbocyanation of chiral allylsilanes was shown to occur with high diastereocontrol, leading to syn β‐silyl nitriles. The origin of the stereocontrol was
[EN] MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF<br/>[FR] LACTAMES MACROCYCLIQUES ET LEUR UTILISATION PHARMACEUTIQUE
申请人:NOVARTIS AG
公开号:WO2005049585A1
公开(公告)日:2005-06-02
The present invention relates to novel macrocyclic compounds of the formula (I) wherein R1, R2, R3, U, V, W, X, Y, Z and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to their preparation, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.
Macrocyclic lactams and pharmaceutical use thereof
申请人:Auberson Yves
公开号:US20070072792A1
公开(公告)日:2007-03-29
The present invention relates to novel macrocyclic compounds of the formula
wherein R
1
, R
2
, R
3
, U, V, W, X, Y, Z and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to their preparation, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.
Macrocyclic Lactams and Pharmaceutical Use Thereof
申请人:AUBERSON Yves
公开号:US20100022500A1
公开(公告)日:2010-01-28
The present invention relates to novel macrocyclic compounds of the formula
wherein R
1
, R
2
, R
3
, U, V, W, X, Y, Z and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to their preparation, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.